anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic spontaneous urticaria (CSU) involves recurrent, pruritic wheals lasting more than 6 weeks in response to various etiologies, including unknown causality. Though most cutaneous reactions to the COVID-19 vaccine series are self-limited and of short duration, more complex presentations including chronic spontaneous urticaria have been described. To the best of our knowledge, this is the first report of chronic spontaneous urticaria following heterologous mRNA COVID-19 booster vaccination that includes vaccination with both forms of the mRNA vaccine. Our patient received Pfizer-BioNTech for the primary series and Moderna for the booster. After failing several therapies, our patient's urticaria was refractory even to omalizumab. The source for chronic spontaneous urticaria development in our patient may be related to the unique humoral response elicited by receipt of a different mRNA vaccine manufacturer.
PURPOSE:To provide a primer compsn. which can firmly bond vinyl chloride resins to diene copolymers, consisting of a vinyl chloride resin or a thermoplastic resin compatible therewith, a diene copolymer and a specified solvent mixture. CONSTITUTION:A compsn. consists of 5-30pts.wt. vinyl chloride resin or thermoplastic resin compatible therewith, 5-30pts.wt. diene copolymer and 40-90pts.wt. solvent mixture of 30-45wt% arom. hydrocarbon which is a good solvent for th diene polymer, 30-45wt% lower fatty acid alkyl ester which is a good solvent for the diene copolymer and highly volatile, and 10-40wt% lower alkyl ketone which is a good solvent for the vinyl chloride resin and highly volatile. The primer compsn. is suitable for use is bonding diene copolymers, particularly styrene/butadiene block copolymer or styrene/isoprene block copolymer to vinyl chloride resins.
The trial will take place in the study area of the Niakhar demographic surveillance system in Senegal, a population representative of rural impoverished Africa. Villages will be randomized to TIV or a beneficial control vaccine-inactivated polio vaccine-and children 6 months to 10 years of age will be targeted for vaccination. Four hundred children will be further enrolled into an immunogenicity and safety substudy which will measure their immune response to vaccination and assess in detail reactions and adverse events to the vaccines in these populations. For evaluation of effectiveness, passive and active surveillance will be conducted to identify laboratory-confirmed influenza among enrolled children and in the population in which they live. Such surveillance will also allow a determination of the rates of influenza and a description of the clinical characteristics of the disease in an African population. With such epidemiologic data, national and global public health officials will have better data for developing future influenza control strategies for either seasonal or pandemic influenza.
This is an open label phase I study for assessing the safety, tolerance and immunogenicity of 3 escalated doses of the test vaccine, BBV87. The study design has four treatment groups - 3 test groups and a control placebo group with 15 subjects in each group. However, the groups will be divided into three study arms: each arm will have 15 subjects of the test vaccine group and 5 subjects of the placebo group. The randomization will be done in a way that allots 5 subjects of the placebo group to each test dose group. All subjects will be screened (via medical history, physical examination and laboratory investigations) to establish the eligibility criteria. This includes negative antibodies, CHIKV IgG, by ELISA method. The test vaccine and placebo will be administered as 3 doses at 28 days interval on day 1±2, 29±2, and 57±2. Vaccine administration will be performed as an in-patient procedure. Subjects will be admitted in CPU 24 hrs prior to vaccine administration, and will be shifted to MICU for vaccination and observed for 48 hrs; and will be discharged upon completion of all clinical monitoring procedures. Laboratory and biochemical tests will be performed as part of clinical monitoring before discharge, and 24 hrs after vaccine administration. Following vaccination, all participants will be monitored throughout the study period for adverse events with daily telephone contacts (for 7 days after each vaccine, and then weekly), interim clinic visits, subject diary cards, and haematological \& biochemical laboratory tests.
The MAP-1 study is designed to validate microRNA and/or pancreatic digestive enzyme biomarkers for the detection and severity assessment of drug-associated AP, for application to the assessment of adverse reactions to drugs in development or drugs already developed for other indications. The study will also assess the clinical utility of these biomarkers in AP from other causes, but is not designed to determine whether the biomarkers could be used in place of amylase and/or lipase in the standard clinical diagnosis of AP or to distinguish between the many differential diagnoses of AP. Selection is in progress of the microRNAs and pancreatic digestive enzyme biomarkers to be validated in this study, this selection being made from prospectively biobank samples obtained in a separate observational study that has separate ethical approval.

The pre-selected microRNAs and pancreatic digestive enzymes will be measured in the blood and urine of patients on admission to hospital with drug-associated acute pancreatitis (Group 1, 75 participants in receipt of one or more drugs on a defined list of drugs associated with acute pancreatitis) or other cause acute pancreatitis (Group 2, 250 participants not in receipt of any of the defined drugs). The same biomarkers will also be measured in blood and urine samples from contrast groups of patients with chronic pancreatitis (Group 3, 25 participants), pancreas cancer (Group 4, 25 participants), type I or II diabetes mellitus (Group 5, 25 participants) and healthy volunteers (Group 6, 100 participants). All participants will be at least 18 years old. MicroRNAs will be measured by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and pancreatic enzymes by mass spectrometry.
Participants enrolled to the IP arm will meet weekly for 14 weeks, biweekly for 10 weeks, and then monthly for the next 18 months. Each session will be led by a study dietitian that has been assigned to that specific health center and will last 1.5 hours. Participants will be allowed to have one-on-one sessions with their dietitian throughout the first two years, twice in the first year and three times in the second year.
BACKGROUND: Stent malapposition (SM) following percutaneous coronary intervention (PCI) for myocardial infarction continues to present significant clinical challenges. In recent years, machine learning (ML) models have demonstrated potential in disease risk stratification and predictive modeling.
HYPOTHESIS: ML models based on optical coherence tomography (OCT) imaging, laboratory tests, and clinical characteristics can predict the occurrence of SM.
METHODS: We studied 337 patients from the Affiliated Hospital of Zunyi Medical University, China, who had PCI and coronary OCT from May to October 2023. We employed nested cross-validation to partition patients into training and test sets. We developed five ML models: XGBoost, LR, RF, SVM, and NB based on calcification features. Performance was assessed using ROC curves. Lasso regression selected features from 46 clinical and 21 OCT imaging features, which were optimized with the five ML algorithms.
RESULTS: In the prediction model based on calcification features, the XGBoost model and SVM model exhibited higher AUC values. Lasso regression identified five key features from clinical and imaging data. After incorporating selected features into the model for optimization, the AUC values of all algorithmic models showed significant improvements. The XGBoost model demonstrated the highest calibration accuracy. SHAP values revealed that the top five ranked features influencing the XGBoost model were calcification length, age, coronary dissection, lipid angle, and troponin.
CONCLUSION: ML models developed using plaque imaging features and clinical characteristics can predict the occurrence of SM. ML models based on clinical and imaging features exhibited better performance.
CAUTION: Glass syringes may malfunction, break, or clog when connected to some Needleless Luer Access Devices (NLADs) and needles. The external collar must remain attached to the syringe (See Figure 1). Spontaneous disconnection of this glass syringe from needles and NLADs with leakage of drug product may occur. Assure that the needle or NLAD is securely attached before beginning the injection. Inspect the glass syringe-needle or glass syringe–NLAD connection before and during drug administration.

Figure 1

1\. Inspect the integrity of the plastic tube, cap and tamper evident seal. Do not use if the tamper evident seal has been damaged.

2\. Break the tamper evident seal when removing the cap to access the syringe.

3\. Push plunger rod slightly to break the stopper loose while tip cap is still on.

4\. Remove tip cap by twisting it off. (See Figure 2)

Figure 2

5\. Connect the syringe to an appropriate injection connection.

6\. Depress plunger rod to deliver the required dose.
Peripheral neuropathy is a definite but unusual complication of Dapsone therapy in non-leprosy patients. Motor loss is predominant. If muscle weakness appears, Dapsone should be withdrawn. Recovery on withdrawal is usually substantially complete. The mechanism of recovery is reported by axonal regeneration. Some recovered patients have tolerated retreatment at reduced dosage. In leprosy this complication may be difficult to distinguish from a leprosy reactional state.
PCT No. PCT/NL89/00030 Sec. 371 Date Dec. 14, 1990 Sec. 102(e) Date Dec. 14, 1990 PCT Filed Apr. 27, 1989.The invention relates to a method of localizing and quantifying regional energy metabolism, in particular regional ischemia, in a warm-blooded living being, comprising administering to said being a diagonstically effective quantity of a radiolabelled L-homocysteine or a radiolabelled functional derivative thereof. The invention further relates to a pharmaceutical composition to be used for performing the above method.
A key step for metastatic outgrowth involves the generation of a deeply altered microenvironment (niche) that supports the malignant behavior of cancer cells. The complexity of the metastatic niche has posed a significant challenge in elucidating the underlying programs driving its origin. Here, by focusing on early stages of breast cancer metastasis to the lung in mice, we describe a cancer-dependent chromatin remodeling and activation of developmental programs in alveolar type 2 (AT2) cells within the niche. We show that metastatic cells can prime AT2 cells into a reprogrammed multilineage state. In turn, this cancer-induced reprogramming of AT2 cells promoted stem-like features in cancer cells and enhanced their initiation capacity. In conclusion, we propose the concept of "reflected stemness" as an early phenomenon during metastatic niche initiation, wherein metastatic cells reprogram the local tissue into a stem-like state that enhances intrinsic cancer-initiating potential, creating a positive feedback loop where tumorigenic programs are amplified.
During surgical endodontics the cortical bone is exposed by elevating a full- thickness tissue flap. Cutting across mucosal blood vessels disturbs perfusion and causes ischemia. On the other hand, preserving sufficient blood flow of the soft tissue segment is important for the postoperative wound healing. In order to minimize the damage of the microvasculature of the operated area, the incision should be properly designed.

The investigators will model surgical incisions by strangulation of the gingiva of healthy human subjects based on the commonly applied endodontic incision such as horizontal, vertical and papilla base. The primary aim is to determine the effect of a short term disruption of the blood flow at the respective region on the surrounding area in order to assess the functionally active collateral circulation. Using Laser Speckle Contrast Analysis (LASCA), which provides blood perfusion data, the investigators will have the possibility to detect functional alterations in gingival microcirculation during and after a short term of strangulation. The secondary aim is to assess the time course of the restoration of the circulation on the affected area.
With the approval of antifibrotic medications to treat patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, radiologists have an integral role in diagnosing these entities and guiding treatment decisions. CT features of early pulmonary fibrosis include irregular thickening of interlobular septa, pleura, and intralobular linear structures, with subsequent progression to reticular abnormality, traction bronchiectasis or bronchiolectasis, and honeycombing. CT patterns of fibrotic lung disease can often be reliably classified on the basis of the CT features and distribution of the condition. Accurate identification of usual interstitial pneumonia (UIP) or probable UIP patterns by radiologists can obviate the need for a tissue sample-based diagnosis. Other entities that can appear as a UIP pattern must be excluded in multidisciplinary discussion before a diagnosis of idiopathic pulmonary fibrosis is made. Although the imaging findings of nonspecific interstitial pneumonia and fibrotic hypersensitivity pneumonitis can overlap with those of a radiologic UIP pattern, these entities can often be distinguished by paying careful attention to the radiologic signs. Diagnostic challenges may include misdiagnosis of fibrotic lung disease due to pitfalls such as airspace enlargement with fibrosis, paraseptal emphysema, recurrent aspiration, and postinfectious fibrosis. The radiologist also plays an important role in identifying complications of pulmonary fibrosis-pulmonary hypertension, acute exacerbation, infection, and lung cancer in particular. In cases in which there is uncertainty regarding the clinical and radiologic diagnoses, surgical biopsy is recommended, and a multidisciplinary discussion among clinicians, radiologists, and pathologists can be used to address diagnosis and management strategies. This review is intended to help radiologists diagnose and manage pulmonary fibrosis more accurately, ultimately aiding in the clinical management of affected patients. ©RSNA, 2024 Supplemental material is available for this article.
PROBLEM TO BE SOLVED: To improve appearance and stability by a method wherein a cap is combined with the upper surface of a container body and a cap is provided to a drainage port at a corner of the cup, and a tunnel-shaped brush insertion port is provided on a side surface of the body. SOLUTION: A cup 2 is combined with the upper surface of a container body 1, and a drainage port 3 is provided at a corner of the cup 2, while a cap 4 is provided on the port 3. A tunnel-shaped coating brush insertion port 5 is preferably provide on a side of the body 1. For using these items, the cap 4 of the port 3 is removed to pour hot water from the port 3, and the cap 4 is placed. While a hairdye is being mixed in the cup 2, a coating operation is performed. The handle of a coating brush, after the coating operation, is inserted into the port 5 from above to store it. When the hairdye heated by the hot water attaches onto the skin of head, pleasant feeling is produced. The container body filled with hot water itself has a weight and hence the body is stabilized. Since the brush can be set up, the external appearance there of is good and functional.
PCT No. PCT/JP96/02494 Sec. 371 Date Mar. 4, 1998 Sec. 102(e) Date Mar. 4, 1998 PCT Filed Sep. 4, 1996 PCT Pub. No. WO97/09318 PCT Pub. Date Mar. 13, 1997The present invention is directed to a pyrimidine derivative of the following formula (1) or a salt of the derivative:    <IMAGE>  (1)  [wherein R1 represents a hydroxyl group, a lower alkoxy group, a phenyloxy group which may have a substituent, an aralkyloxy group which may have a substituent, or -NR2R3; X represents an oxygen atom or N-R4; m is 2 or 3; and n is 1 or 2 (wherein each of R2 and R3, which are identical to or different from each other, represents a hydrogen atom, a hydroxyl group, a lower alkyl group which may have a substituent, a phenyl group which may have a substituent, an aralkyl group which may have a substituent, or a heterocyclic group which may have a substituent; R4 represents a lower alkyl group, a phenyl group, a formyl group, or a lower alkoxycarbonyl group)], as well as to a medicine containing the derivative or salt as the active ingredient. The compounds exhibit strong binding inhibitory activity against endothelin having potent vasoconstrictive effect. Therefore, the compounds are effective as remedies for various diseases including circulatory diseases.
PROBLEM TO BE SOLVED: To obtain a skin cleansing preparation excellent in portability and comfortable in use owing to cleansing of the skin by taking its particles on the hand after adding a small amount of water to them with water by including a surfactant and granulating or tableting into granules each with a specific size. SOLUTION: This granular cleansing preparation is obtained by including a surfactant, and granulating or tableting into granules each with a size of 2-12 mm. As for the surfactant, an alkylsulfosuccinate, N-acrylglutamate, acryllactate or the like, as a kind of anionic surfactant, is preferably used. The amount of the surfactant to be included is preferably 10-80 pts.wt., more preferably 15-65 pts.wt. per 100 pts.wt. of the cleansing preparation. This cleansing preparation includes preferably a physiologically active ingredient as well as the surfactant. As for the physiologically active ingredient, e.g. an enzyme, moisturizer, bleaching agent, antioxidant, α-hydroxy acid (salt), extract from plant is preferably used.
Disclosed are compositions for use in forming articles subject to frictional force or for use in tribological systems and articles formed therefrom. Such compositions comprise at least one crosslinkable aromatic polymer matrix material which remains operable at a PV of at least about 75,000 psi-ft./min or more. Such at least one crosslinkable polymer may also be used as a filler in crosslinked form in a wear matrix material in further compositions herein. The wear resistance may be enhanced from about 200% to up to about 850% in comparison with known wear compositions or with respect to use of the same aromatic polymer filler that is not crosslinked. Methods of improving wear resistance, or the PV limit of wear compositions are also disclosed. Methods and compositions for substantially retaining dimensional stability and avoiding catastrophic failure about a critical transition temperature using the compositions herein are further disclosed.
Up to 33 patients will be enrolled to receive the maximum tolerated dose (determined in phase I) over a 28 day cycle. Azacitidine will be given at the standard dose over a 28 day cycle.
If patients were De novo or their disease-free interval (DFI) were more than or equal to 12 months and were randomized to experimental arm, they would receive VEGFR BP102 with nab-palitaxel (Nab-P). And maintained by VEGFR and capecitabine if intolerable toxicity was observed with no progression.
Pulpectomy for primary teeth involves root canal preparation followed by obturation with a resorbable material. Zinc oxide eugenol (ZOE) is the most widely used obturating material. The main ZOE disadvantages are the difference in rate of resorption compared to the root, and limited antimicrobial activity. ZOE is formed when crude eugenol is mixed with zinc oxide. the set material easily hydrolyzes, resulting in free eugenol release which can be harmful to human soft tissues; this motivated the search for a new eugenol substitute to be combined with zinc oxide. Olive oil is a vegetable oil that comprises antioxidants, carotenoids, oleuropein, and oleocanthal, a phenolic component that significantly contributes to its antibacterial and anti-inflammatory properties. ozone in the form of ozonated olive oil, have the ability to produce nascent oxygen deep into the treated area without triggering irritation so, improved rheological characteristics, increased intracellular ATP, stimulated cellular metabolism, and expression of cytokines related to healing, particularly Transforming Growth Factor.
Will receive intravenous Saline solution placebo bolus dose in the Emergency Center over 10 minutes. The subject will also receive intravenous Saline solution over 8 hours prior to surgery. Another dose will be administered at the time of incision and the final dose three hours later.
<P>PROBLEM TO BE SOLVED: To obtain a medicament intended for the treatment of generalized anxiety disorder.  <P>SOLUTION: Agomelatine, namely N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide is used for the treatment of generalized anxiety disorder. Agomelatine has an excellent receptor profile besides observed efficacy. The withdrawal syndrome observed as an adverse effect normally caused by an antipsycotic drug is not observed in agomelatine and agomelatine is used in the most suitable therapy. The medicine composition is obtained by using agomelatine, its hydrate, crystal form and an additional salt with a pharmacologically acceptable acid or a base.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The present invention relates to a cellulose-heparin complex obtained by compounding nano crystal cellulose (NCC) and heparin, and a preparing method thereof. The complex has the structure that in a right formula, R is equal to CH2, CH3CH, OHC-CH, OHCCH2CH2CH2CH, (CH2O)4, (CH2O)5OHCCH2CH2CH2CH(OH)CH, CH2CH2SO2CH2CH2 and CH2CH(OH)CH2, wherein m is from 8 to 25, and n is from 25 to 75. The present invention also provides a method for preparing the complex by the cross-linking reaction and the ring opening cross-linking reaction of the NCC and the heparin through aldehyde and an active vinyl compound. The complex maintains the anticoagulated performance and a hematolysis function of the heparin so that medicine is not exhausted in vitro to be become long acting medicine. Nano medicine can be circulated in the large and the small blood vessel of a human body, can not block the blood vessel and has good compatibility with the human body. The aim for curing cardiovascular diseases is achieved, and the present invention has favorable application prospects.
TThe generic iCBT program was based on contemporary CBT techniques adapted for stress-related disorders, and recovery from work training inspired by Hahn et al. \[2011\]. The iCBT consisted of ten modules distributed over ten weeks, with modules lasting 60-120 min per week. In the first module (introduction), the participants received information about the outline of the program, stress physiology and defined individual treatment goals. During the second week participants were introduced to different recovery techniques and applied relaxation. The third and fourth week contained exercises related to behavioral activation, work-home balance, and values-based action skills. Between weeks five and ten, participants were able to choose between different exposure-based exercises. In addition, participants with insomnia could choose to focus on sleep management.